miR‐619‐5p and cardiogenic shock in patients with ST‐segment elevation myocardial infarction

Rafael Escate,Teresa Padró,Rosa Suades,Jordi Sans‐Roselló,Yvan Devaux,Päivi Lakkisto,Veli‐Pekka Harjola,Alessandro Sionis,Lina Badimon
DOI: https://doi.org/10.1111/eci.14186
2024-02-21
European Journal of Clinical Investigation
Abstract:By high throughput (profiling) analysis of plasma miRNAs, we identified a differential miRNA‐signature in patients with cardiogenic shock (CS) after STEMI. miR‐619‐5p showed the highest difference between CS and Non‐CS patients in plasma and miR‐619‐5p levels positively correlate with the CS risk scores (GRACE and Cardshock). Quantification of plasma miR‐629‐5p and TNF‐alpha, at the time of hospital admission, associates with mortality risks at 30 days. Background Cardiogenic shock (CS) is a severe myocardial dysfunction secondary to various cardiac conditions including ST‐segment elevation acute myocardial infarction (STEMI) and associated with a high risk of death. Little is known on epigenetic determinants in CS. Here, we investigated plasma miRNAs in relation to CS stratification in STEMI‐patients. Methods STEMI‐patients (n = 49), with (CS, n = 25) and without CS (non‐CS, n = 24) fulfilling inclusion criteria were included from HSCSP‐cohort (Derivation‐cohort). CS‐miRNAs were analysed by Affymetrix‐microarray and RT‐PCR. Results were validated in a second cohort of CS‐patients (CardShock: n = 35) with similar inclusion/exclusion criteria as the derivation cohort. In silico analysis were performed to identify potential miRNA target genes. Results Of the 5‐miRNA signature obtained from microarray analysis, miR‐619‐5p showed higher levels in CS than in Non‐CS patients (p = .003) and discriminating power for CS by ROC (AUC: .752, p = .003). miR‐619‐5p directly associated with risk scores [GRACE, p = .001; CardShock, p
medicine, general & internal, research & experimental
What problem does this paper attempt to address?